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Colorectal cancer (CRC) is a major cause of death worldwide.
Studies suggest that dietary ﬁbre offers protection perhaps by
increasing colonic fermentative production of butyrate. This
study examined the importance of butyrate by investigating the
effects of resistant starch (RS) and butyrylated-RS on azoxyme-
thane (AOM)-induced CRC in rats. Four groups (n 5 30 per
group) of Sprague–Dawley rats were fed AIN-93G-based diets
containing a standard low-RS maize starch (LAMS), LAMS 1
3% tributyrin (LAMST), 10% high-amylose maize starch
(HAMS) and 10% butyrylated HAMS (HAMSB) for 4 weeks.
Rats were injected once weekly for 2 weeks with 15 mg/kg
AOM, maintained on diets for 25 weeks and then killed. Butyrate
concentrations in large bowel digesta were higher in rats fed
HAMSB than other groups (P < 0.001); levels were similar in
HAMS, LAMS and LAMST groups. The proportion of rats de-
veloping tumours were lower in HAMS and HAMSB than LAMS
(P < 0.05), and the number of tumours per rat were lower in
HAMSB than LAMS (P < 0.05). Caecal digesta butyrate pools
and concentrations were negatively correlated with tumour size
(P < 0.05). Hepatic portal plasma butyrate concentrations were
higher (P < 0.001) in the HAMSB compared with other groups
and negatively correlated with tumour number per rat (P < 0.009)
and total tumour size for each rat (P 5 0.05). HAMSB results in
higher luminal butyrate than RS alone or tributyrin. This is asso-
ciated with reduced tumour incidence, number and size in this
rat model of CRC supporting the important protective role of
butyrate. Interventional strategies designed to maximize luminal
butyrate may be of protective beneﬁt in humans.
Introduction
Colorectal cancer (CRC) is a common malignancy in Western socie-
ties resulting in 8% of all cancer deaths (1) and is emerging as a sig-
niﬁcant cause of morbidity and mortality in several Asian and Eastern
European countries as they adopt western dietary habits and lifestyles.
This cancer is considered mostly preventable by appropriate diet and
associated lifestyle factors (2).
Resistant starch (RS) is dietary starch that escapes digestion in the
small intestine. It is fermented by colonic bacteria with the production
of short chain fatty acids (SCFA). Consumption of RS by humans has
been shown to improve the colonic environment by softening stools,
increasing faecal bulk, decreasing faecal pH, increasing luminal SCFA
concentrations (3) and reducing the accumulation of potentially harm-
ful by-products of protein fermentation (4). Recent animal studies show
that RS prevents colonic DNA damage inrats fed high protein diets (5).
The main SCFA produced by colonic fermentation of carbohydrate
are acetate, propionate and butyrate. These SCFA have important roles
in the maintenance of bowel health that include increasing colonic blood
ﬂow, improving mineral and water absorption from the colon and the
maintenance of low colonic pH (6). Butyrate, which is the preferred
energy source for colonocytes (7), mayb ep r o t e c t i v eag a i n s tl ar g eb o w el
cancerby inhibiting histone deacetylase thereby enhancing the apoptotic
deletion of genetically damaged cells (8) through a histone hyperacety-
lation-mediated pathway (9,10). Butyrate has also been shown to inhibit
proliferation and induce differentiation of cancer cells in vitro (11,12).
Strategies to increase colonic levels of SCFA, particularly butyrate,
may have clinical and public health beneﬁts. However, there may be
limits to the usefulness of promoting RS consumption to increase
butyrate levels as the microﬂora of some individuals have limited
capacity to ferment certain types of RS, the SCFA proﬁle produced
can vary with RS source (13) and dietary ﬁbre is not universally
tolerated. Starches acylated to a degree of substitution of 0.2–0.25
(i.e. 0.2–0.25 of the hydroxyl groups on each starch D-glucopyranosyl
unit were derivatized or replaced by substituent acids) have been
shown to be an effective means of delivering speciﬁc SCFA to the
colon in both animals (14,15) and humans (16). The SCFA, esteriﬁed
to the starch carrier molecule, are liberated by bacterial enzymes and
are absorbed and utilized by the colonocytes or gut microbes.
This study investigated the importance of butyrate by examining
the effects of RS and butyrylated-RS on tumour development in rats
treated with azoxymethane (AOM). The effect of systemic butyrate
absorbed from the small intestine was also examined by the inclusion
of rats fed tributyrin (LAMST).
Materials and methods
Animals and diets
Adult male Sprague–Dawley rats (198 ± 2 g) were purchased from the Animal
Resource Centre, Murdoch University, Western Australia. The rats were
housed in wire-bottomed cages in a temperature-controlled room (22–24C)
with a 12 h light–dark cycle (lights on 8:00–20:00). They were allocated
randomly into four groups (n 5 30 per group) with approximately equal body
weights and given free access to water and diet throughout the study.
The experimental diets were based on a control AIN-93G (17) diet that
contained 530 g standard low-amylose maize starch, 200 g casein, 70 g corn
oil and 50 g a-cellulose/kg of diet. The choline, methionine, minerals, vitamins
and antioxidant were added as described previously (15). The amount of stan-
dard maize starch in the diet was reduced to allow for the addition of exper-
imental starches and tributyrin. The experimental diets were control (LAMS,
lowRS),low-amylose maizestarch with3% tributyrin(LAMST, lowRS),10%
high-amylose maize starch (HAMS, high RS) or 10% butyrylated HAMS
(HAMSB, high RS). The latter was manufactured by National Starch Food
Innovation and had a degree of substitution of 0.25. HAMS and HAMSB were
cooked with water and spray dried (to minimize crystallite formation) as de-
scribed previously (18) before addition to the diets. This process was used to
mimic the condition of starches consumed in foods by humans as cooking
changes the production and delivery of butyrate to the colon by starches
(15). All diets were prepared regularly at CSIRO and stored at 4C. The rats
were fed fresh diet daily.
Abbreviations: AOM, azoxymethane; CRC, colorectal cancer; CSIRO, Com-
monwealth Scientiﬁc and Industrial Research Organisation; HAMS, high-
amylosemaizestarch;HAMSB,butyrylatedhigh-amylosemaizestarch;LAMS,
low-amylose maize starch; RS, resistant starch; SCFA, short chain fatty acids.
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15 mg of AOM/kg (Sigma Chemical Co., St Louis, MO). The rats were main-
tained on their experimental diets and were injected with the same dose of
AOM a week later. They were monitored closely until the termination of the
experiment 25–27 weeks post-initial AOM injection. Rats were anaesthetized
with halothane and blood collected into heparin-treated tubes from the hepatic
portal vein. The small and large intestines and caecum were opened longitu-
dinally, digesta collected and the epithelial surface cleaned with 0.15 mM
NaCl/l. The colon was divided into two equal length parts designated proximal
and distal colon. The location, number and size of visible tumours were re-
corded for each animal before the tumours were collected and ﬁxed in 10%
buffered formalin, embedded in parafﬁn blocks and processed by routine his-
tological procedures for subsequent haematoxylin and eosin staining.
All procedures involving animals were approved by the CSIRO Human
Nutrition Animal Ethics Committee and complied with the Australian Code
of Practice (19).
Analytical procedures
Analysis of SCFA, dry matter and pH was undertaken as described previously
(15,20). All tumours were examined histologically by a single independent
observer unaware of the dietary treatment and categorized into adenomas and
adenocarcinomas (invasive tumours) based on the criteria described previously
(21). The ‘tumour incidence’ was deﬁned as the proportion of rats in a group
that had at least one tumour in the small or large bowel. The ‘size’ of each
tumour was calculated using the formula:
Tumour area index5p½ðD1   D2Þ=4 
where D1 and D2 are the length and width of each tumour.
Statistical analyses
GraphPad Prism version 4.0 for Windows (http://www.graphpad.com) com-
puter software was used for statistical analyses. Parametric data (body weight,
organ weights and digesta measures) were analysed using one-way analysis of
variance and Tukey’s post hoc multiple comparison test. Tumour indices were
compared between treatment groups using either Kruskal–Wallis test with
Dunn’s post hoc tests or Mann–Whitney two-tailed t-tests for non-parametric
data. Tumour incidence data were analysed using Pearson’s v2 test using
contingency tables. The relationships between butyrate and tumour measures
were determined by non-parametric Spearman-ranked correlations. Data
are expressed as mean ± SEM with statistical signiﬁcance indicated when
P , 0.05.
Results
Growth rates were similar in all the experimental groups and there
were no signiﬁcant differences in ﬁnal body weights between the
dietary treatments (mean for all groups 627 ± 7 g, Table I). Two rats
were euthanased early due to events unrelated to the experimental
procedures (from group LAMS in week 9; HAMSB, week 23). Seven
rats were euthanased within 4 weeks of their scheduled dates because
they showed possible symptoms of CRC including weight loss and
rectal bleeding; tumour end points were obtained from these animals.
Caecal tissue and digesta weights were higher in rats fed HAMSB
than all other groups (P , 0.001), and caecal tissue weight was high-
er in HAMS rats compared with LAMST (P , 0.01) (Table I). Caecal
digesta pH was different between groups with pH in HAMSB-fed rats
lower than the other groups (P , 0.001), and the pH in the HAMS
group lower than the LAMS (P , 0.001) and LAMST (P , 0.05)
groups (Table I). The digesta pH fell from caecum to distal colon in all
groups except HAMSB; in the distal colon, the digesta pH of rats fed
LAMS was higher than HAMS (P , 0.01).
Caecal and proximal and distal colonic digesta butyrate concentra-
tions were higher in rats fed HAMSB than other groups (P , 0.001)
and were similar in HAMS, LAMS and LAMST groups (Figure 1).
Digesta SCFA pool sizes, calculated by multiplying the digesta wet
weights by the concentrations of each of the fatty acids measured
(acetate, propionate and butyrate), are shown in Table II. Digesta
butyrate pool sizes were consistently larger throughout the large
bowel in rats fed HAMSB (P , 0.05–0.001). Caecal pools of acetate
and propionate and proximate and distal colonic pools of propionate
were also larger in rats fed HAMSB (P , 0.001–0.05). Caecal and
distal pools of propionate were higher in HAMS than LAMST or
LAMS groups (P , 0.05–0.001), and proximal pools of propionate
were higher in HAMS than LAMST (P , 0.001).
Hepaticportalplasmabutyrateconcentrationwashigher(P , 0.001)
in the HAMSB compared with the other groups (Figure 1). Dietary
tributyrin (LAMST) increased hepatic portal butyrate concentration
compared with LAMS to levels similar to HAMS (P , 0.001).
More large bowel tumours were found in the distal colon rather
than the proximal colon (P , 0.02); however, a greater proportion of
proximal tumours was adenocarcinomas (13 of 32) compared with the
distal colon, where most tumours were adenomas (55 of 67)
(P , 0.02). The size of caeco-colonic adenomas was positively and
signiﬁcantlycorrelatedto thedistanceofthe adenomasfrom therectum
(Spearman r 5 0.310, P , 0.008, n 5 74) with larger adenomas tend-
ing to be closer to the caecum. The reverse was the case for adenocar-
cinomas, with larger adenocarcinomas tending to be closer to the
rectum (Spearman r 5  0.403, P , 0.05, n 5 25). There was no
effect of diet on the distribution of tumours based on size or tumour
type i.e. the ratio of adenomas to adenocarcinomas in the proximal and
distal colons was not signiﬁcantly different between treatment groups.
Large bowel tumour incidence (proportion of rats per group with
tumours) was lower in HAMSB and HAMS compared with LAMS
group (P , 0.05). Tumour number (number of tumours per group)
was lower in HAMSB compared with LAMS (P , 0.05). There was
Table I. Final measures of rats fed diets containing low-amylose maize
starch (LAMS), LAMS with 3% tributyrin (LAMST), HAMS and
butyrylated HAMS (HAMSB)
LAMS LAMST HAMS HAMSB
Body weight (g) 635 ± 15 621 ± 18 638 ± 14 616 ± 25
Caecal tissue
weight (g)
0.84 ± 0.02
a 0.78 ± 0.02
a,b 0.93 ± 0.03
a 1.19 ± 0.03
Caecal digesta (g) 1.46 ± 0.07
a 1.41 ± 0.09
a 1.70 ± 0.09
a 2.27 ± 0.08
Caecal digesta pH 7.12 ± 0.04
a,c 7.07 ± 0.04
a,d 6.92 ± 0.03
a 6.69 ± 0.04
Distal colonic
digesta pH
6.97 ± 0.05
b 6.85 ± 0.07 6.66 ± 0.05 6.77 ± 0.06
Values are mean ± SEM, n 5 28–30.
aSigniﬁcantly different from HAMSB, P , 0.001.
bSigniﬁcantly different from HAMS, P , 0.01.
cSigniﬁcantly different from HAMS, P , 0.001.
dSigniﬁcantly different from HAMS, P , 0.005 within each row of data.
Fig. 1. Concentration of butyrate in the digesta of the caecum, proximal and
distal colon (mM; n 5 28–30)and hepatic portal plasma (mM; n 5 26–30) of
rats fed diets containing low-amylose maize starch (LAMS; open bars),
LAMS with 3% tributyrin (LAMST; light grey bars), (HAMS; dark grey
bars) and butyrylated HAMS (HAMSB; black bars) (mean ± SEM).
aSigniﬁcantly different from HAMSB, P , 0.001; bsigniﬁcantly different
from HAMS, P , 0.05 and csigniﬁcantly different from LAMST, P , 0.001
within each gut region or hepatic portal plasma.
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group compared with the LAMS (P , 0.055). Caecal butyrate pools
and concentrations were signiﬁcantly and negatively correlated with
the number of large bowel tumours per rat (P , 0.03, r 5  0.206 and
P , 0.04, r 5 0.198, respectively), whereas there was no relation-
ship between distal butyrate levels and tumour number. The total
tumour area for each rat was lower in the HAMBS than LAMS group
(P , 0.05). The caecal butyrate pools and total large bowel tumour
area for each rat were signiﬁcantly and negatively correlated
(P , 0.05, r 5  0.185). Hepatic portal plasma butyrate concentra-
tion was negatively correlated with tumour number per rat (Spearman
r 5  0.243, P , 0.009) and total tumour area index for each rat
(Spearman r 5  0.184, P 5 0.05).
Most small intestinal adenomas were found in the proximal small
intestine (data not shown). Therewere no signiﬁcant differences in the
incidence, numbers and ratio of adenomas to adenocarcinomas in the
small intestine between groups (Table III). Tumours in the small in-
testine of rats fed LAMST were signiﬁcantly larger than those in the
rats fed LAMS (P , 0.05) but the total small intestinal tumour area
per rat was not signiﬁcantly affected by diet.
Discussion
Acylated starches were designed to promote large bowel health by
providing a vehicle for the rapid and sustained delivery of SCFA,
particularly butyrate, to the colon (22). Low levels of colonic SCFA
in individual humans may result either from low consumption of di-
etary ﬁbre or from an inadequate fermentative capacity of the colonic
microﬂora. Earlier animal studies have shown that acylated starches
are twice as effective as HAMS in raising large bowel SCFA levels of
the acid that has been esteriﬁed (14,15). The present data conﬁrm
those previous experiments and show that while both HAMS and
HAMSB raise total SCFA, the greatest increase in butyrate was with
the butyrylated SCFA. HAMSB was particularly effective in raising
butyrate concentrations in the distal colon, which is the site of most
CRC in humans.
This study examined the importance of butyrate by investigating
the effects of RS (a dietary ﬁbre) and butyrylated-RS on levels of
butyrate in the large bowel and their impact on intestinal tumorigen-
esis in an established animal model of CRC. The results from this
study are consistent with previous experiments showing that dietary
RS reduces CRC incidence in rats treated with AOM (23–26). The
importance ofbutyratetothis protection is demonstrated by the ability
of an RS-equivalent HAMSB to achieve greater protection and higher
butyrate levels. Statistical examination of the data showed that this
effect correlated with caecal butyrate pools and concentrations and
hepatic portal butyrate concentrations.
The total tumour size per rat was also signiﬁcantly lower in the
HAMSB than LAMS group, which reﬂects a lower incidence and
smaller size of tumours in rats fed HAMSB. This further supports
Table II. Digesta SCFA pools (micromoles) of rats fed diets containing low-amylose maize starch (LAMS), LAMS with 3% tributyrin (LAMST), HAMS and
butyrylated HAMS (HAMSB)
Diet Caecal SCFA pools Proximal colon SCFA pools Distal colon SCFA pools
Acetate Propionate Butyrate Acetate Propionate Butyrate Acetate Propionate Butyrate
LAMS 107.7 ± 7.2
a 30.0 ± 1.8
a,b 21.3 ± 1.6
a 44.1 ± 4.2 11.4 ± 1.1
a 7.1 ± 0.7
a 40.9 ± 3.8 9.5 ± 0.8
a,c 7.8 ± 0.8
a
LAMST 99.8 ± 7.6
a 27.8 ± 2.3
a,b 22.0 ± 1.7
a 31.6 ± 3.1
b 8.1 ± 0.7
a,c 5.3 ± 0.6
a 36.7 ± 4.1
c 8.7 ± 0.9
a,c 7.6 ± 1.0
a
HAMS 132.2 ± 11.8
a 53.5 ± 4.6
a 36.2 ± 4.0
a 47.2 ± 4.8 17.2 ± 1.6
a 9.2 ± 0.9
a 55.4 ± 5.7 20.8 ± 2.1
d 12.8 ± 1.9
d
HAMSB 237.2 ± 26.8 125.7 ± 11.1 125.5 ± 12.5 45.5 ± 4.3 23.5 ± 2.3 18.7 ± 2.0 51.1 ± 5.0 29.5 ± 2.9 19.4 ± 2.0
Values are mean ± SEM, n 5 28-30 for caecal; 24–30 for proximal colon; 24–27 for distal colon.
aSigniﬁcantly different from HAMSB, P , 0.001.
bSigniﬁcantly different from HAMS, P , 0.05.
cSigniﬁcantly different from HAMS, P , 0.001.
dSigniﬁcantly different from HAMSB, P , 0.05 within each column of data.
Table III. Indices of AOM-induced small and large bowel tumours in rats fed diets containing low-amylose maize starch (LAMS), LAMS with 3% tributyrin
(LAMST), HAMS and butyrylated HAMS (HAMSB) (mean ± SEM)
LAMS LAMST HAMS HAMSB
Number of rats 29 30 30 29
Incidence of tumours (%)
a
Small intestine 27.6 16.7 30.0 20.7
Large bowel
b 65.5
c,d 56.7 40 37.9
Number tumours per rat
Small intestine 0.4 0.2 0.4 0.2
Large bowel
e 1.3
c 0.9 0.6 0.5
Average tumour area (tumour area index)
Small bowel 35.9 ± 11.5
f 146.9 ± 70.5 49.0 ± 10.2 51.8 ± 11.0
Large bowel 26.2 ± 8.8 21.9 ± 4.6 49.5 ± 14.7 18.0 ± 5.1
Total tumour area per rat
Small bowel 13.6 ± 5.8 29.4 ± 17.3 19.6 ± 6.9 10.7 ± 4.5
Large bowel
e 34.3 ± 12.7
c 19.8 ± 4.7 31.4 ± 12.7 9.3 ± 3.5
Tumour type (large intestine)
Adenoma (number)
a 27 24 12 11
Adenocarcinoma (number)
a 11 3 7 4
aAnalysed using Pearson’s v2 test.
bContingency comparison between two groups.
cSigniﬁcantly different from HAMSB, P , 0.05.
dSigniﬁcantly different from HAMS, P , 0.05.
eAnalysed using Mann–Whitney non-parametric t-tests between two groups.
fSigniﬁcantly different from LAMST, P , 0.05.
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may have a role regulating the initiation and growth of large bowel
tumours.
The relationship between tumour size and butyrate pool was stron-
ger for the caecum than the colon, which may reﬂect the large bowel
physiology of the rat in which bacterial activity occurs principally in
the caecum.
There was no effect of tributyrin on tumour development in the
large bowel. Tributyrin (glycerol tributyrate) is absorbed in the small
intestine, raising free butyrate concentrations in peripheral plasma for
up to 4 h (27). Tributyrin has been recommended for clinical evalu-
ation as a possible treatment for leukaemia (28) but has not been
found to reduce the incidence of AOM-induced CRC in mice (29).
At the level of tributyrin included in the LAMST diet in this study
(3%), hepatic portal plasma butyrate concentrations were similar to
those that resulted from ingesting the HAMS diet. In a previous study
(unpublished data), hepatic portal butyrate concentrations up to 1.0
mM were recorded in individual rats fed 3% tributyrin; however, these
levels were not associated with increased butyrate concentrations in
peripheral plasma. These data suggest that 3% tributyrin may not
increase levels of systemically delivered butyrate to the large bowel
and that butyrate absorbed from the small intestine in the rat is in-
effective in altering large bowel CRC induced by AOM.
Genomic instability is a prerequisite for oncogenesis and the gen-
otoxic effects of AOM are thought to be responsible for tumour
initiation leading to the development of aberrant crypts, adenomas
and eventually invasive adenocarcinoma. Butyrate could inhibit this
process either by promoting apoptosis (8) or repair in damaged
colonocytes during the initiation phase or by suppressing the growth
of cells with damaged DNA (30). Alternatively, butyrate may be
reducing tumourgrowth by inhibiting hypoxia-induced angiogenesis
(31,32). It is not clear which mechanism(s) is operating. Tumour
numbers and incidence were lower in HAMSB than in LAMS.
The size of neoplastic lesions is an important factor clinically as
large adenomas are more likely to progress to adenocarcinomas
(33). Progression to adenocarcinoma may be the consequence of
adenoma cells acquiring resistance to butyrate due to the deregula-
tion of genes involved with the processes of apoptosis, proliferation
and differentiation (34), resulting in cells with increased transfor-
mation potential (35). However, the number of adenomas relative to
adenocarcinomas in this experiment was not affected by dietary
treatment, suggesting that increased luminal butyrate suppressed
oncogenesis at all stages. This conclusion is similar to that drawn
from studies on dietary protein-induced genetic damage in rats (36)
where feeding HAMS opposed double-stranded DNA break forma-
t i o ni nc o l o n o c y t e s .
RS has been reported to reduce the number of colonic adenocarci-
nomas in AOM-treated rats (24) fed diets containing no ﬁbre and high
fat levels. This may be attributed to the high ratio of colonic adeno-
carcinomas in the control animals in this trial compared with the
current trial, whereas the levels of adenomas and adenocarcinomas
in the RS-fed animals were almost identical in both studies.
The present data also conﬁrm the ﬁndings of other studies that
intake of RS increases caecal digesta weight and decreases digesta
pH, which can be interpreted as improving bowel health (3). Butyr-
ylation leads to increased resistance to small intestinal amylolysis and
increased passage of starch to the caecum. Furthermore, the HAMS
and HAMSB used in this study were cooked, and as HAMSB appears
to be more resistant to small intestinal digestion following cooking
than HAMS (15), more fermentative substrate would be delivered to
the large bowel of rats fed this diet.
The size of individual tumours, but not incidence, was increased
in the small intestine of the LAMST group. This effect was un-
expected and was not reported in the one other study we are aware
of involving dietary tributyrin in AOM-treated rodents (29). In hu-
mans, sporadic cancers are normally rare in the small compared
with the large intestine, which may be due to a range of factors
including the high level of spontaneous apoptosis in this organ
protecting against low-level DNA damage (37). Glutamine and glu-
cose are preferred ahead of SCFA as energy substrates by jejunal
enterocytes (38) that would normally be exposed to low-digesta
butyrate levels, suggesting nutritional factors controlling cellular
apoptosis may differ in the small and large intestine. Other workers
have reported an increase in small intestinal tumour incidence, but
not size, in response to RS (39) in mice with a targeted mutant gene
resulting in spontaneous small intestinal tumours. In the AOM-
treated rats in this study, HAMS did not increase small intestinal
tumour size or incidence, supporting the epidemiological evidence
that high-RS diets do not enhance the risk of tumourigenesis in the
small intestine (40).
The current study demonstrates that large bowel and hepatic portal
venous butyrate levels correlated negatively with tumour indices in an
accepted animal model of CRC. Butyrate was raised by HAMS rela-
tive to the LAMS control, but the highest butyrate levels were
achieved with HAMSB, indicating the greater potential effectiveness
for this modiﬁed starch to signiﬁcantly improve bowel health and
reduce the risk of developing CRC. Further work is necessary to de-
termine the effectiveness of HAMSB in opposing initiation or pro-
gression of experimental carcinogenesis.
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